ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO [PDF]
F. Carlos+4 more
openalex +1 more source
Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]
Bopp AR+10 more
europepmc +1 more source
CLL bei Älteren: Ibrutinib in der Erstlinie bald schon Standard? [PDF]
Barbara Kreutzkamp
openalex +1 more source
Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma [PDF]
Simone Critchlow+6 more
openalex +1 more source
A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network. [PDF]
Majrashi A+6 more
europepmc +1 more source
IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL [PDF]
Paula Cramer+19 more
openalex +1 more source
Ibrutinib therapy for lymphoplasmacytic lymphoma [PDF]
Margaret J. Helber+5 more
openaire +3 more sources
Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. [PDF]
Othman I+9 more
europepmc +1 more source